Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with primary immunodeficiency~* Patients who have received stable IVIG therapy at 3- or 4-weekly intervals for at least 6 months~Key Exclusion Criteria:~* Newly diagnosed PID~* Allergic reactions to immunoglobulins or other blood products~* Administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs~* Concomitant diseases such as hypoalbuminemia, protein-losing enteropathies, kidney diseases with proteinuria, malignancies of lymphoid cells (e.g. lymphocytic leukemia), and recent history of migraine~* History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IgPro10 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).